Trial Profile
A Study Assessing Incidence and Incidence Rate Ratios (IRRs) of Hospital Admissions Among Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Newly Treated With Enzalutamide (ENZA) or Abiraterone (ABI)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jul 2017
Price :
$35
*
At a glance
- Drugs Abiraterone (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 02 Jul 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.